Adopting the International Consensus on ANA Patterns (ICAP) classification for reporting: the experience of Italian clinical laboratories
Abstract The indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA) is still considered the reference method to detect anti-nuclear antibodies (ANA) because of its high sensitivity and represents a relevant tool for the diagnosis of autoimmune rheumatic diseases. During the last decade, the International Consensus on ANA Patterns (ICAP) initiative promoted harmonization and understanding of HEp-2 IFA staining pattern nomenclature, as well as promoting their use in patient care by providing interpretation for HEp-2 IFA test results. In conjunction with a nationwide survey on the evolution of autoantibody diagnostics in autoimmune rheumatic diseases, we focused on the adherence of the Italian laboratories to the ICAP nomenclature analyzing its lights and shadows. The recent ICAP-oriented report, largely used today among Italian laboratories, also represents a further step in harmonizing and improving communication with the clinicians, adding value to laboratory findings and helping with critical clinical decisions..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Clinical chemistry and laboratory medicine - 62(2023), 5 vom: 19. Okt., Seite 830-834 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Infantino, Maria [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2023 Walter de Gruyter GmbH, Berlin/Boston |
|---|
| doi: |
10.1515/cclm-2023-0752 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY009499156 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY009499156 | ||
| 003 | DE-627 | ||
| 005 | 20240406003622.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/cclm-2023-0752 |2 doi | |
| 035 | |a (DE-627)GRUY009499156 | ||
| 035 | |a (DE-B1597)cclm-2023-0752-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.46 |2 bkl | ||
| 100 | 1 | |a Infantino, Maria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adopting the International Consensus on ANA Patterns (ICAP) classification for reporting: the experience of Italian clinical laboratories |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston | ||
| 520 | |a Abstract The indirect immunofluorescence assay on HEp-2 cells (HEp-2 IFA) is still considered the reference method to detect anti-nuclear antibodies (ANA) because of its high sensitivity and represents a relevant tool for the diagnosis of autoimmune rheumatic diseases. During the last decade, the International Consensus on ANA Patterns (ICAP) initiative promoted harmonization and understanding of HEp-2 IFA staining pattern nomenclature, as well as promoting their use in patient care by providing interpretation for HEp-2 IFA test results. In conjunction with a nationwide survey on the evolution of autoantibody diagnostics in autoimmune rheumatic diseases, we focused on the adherence of the Italian laboratories to the ICAP nomenclature analyzing its lights and shadows. The recent ICAP-oriented report, largely used today among Italian laboratories, also represents a further step in harmonizing and improving communication with the clinicians, adding value to laboratory findings and helping with critical clinical decisions. | ||
| 700 | 1 | |a Bizzaro, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a de Melo Cruvinel, Wilson |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Edward K.L. |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, Luis E.C. |e verfasserin |0 (orcid)0000-0001-8742-9931 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical chemistry and laboratory medicine |d De Gruyter, 1998 |g 62(2023), 5 vom: 19. Okt., Seite 830-834 |h Online-Ressource |w (DE-627)GRUY000051497 |w (DE-600)1492732-9 |w (DE-576)088704882 |x 1437-4331 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2023 |g number:5 |g day:19 |g month:10 |g pages:830-834 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1515/cclm-2023-0752 |m X:VERLAG |x 0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.46 |j Klinische Pathologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 62 |j 2023 |e 5 |b 19 |c 10 |h 830-834 | ||